Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Organon & Co. (NYSE: OGN) announced fourth quarter and full-year 2025 financial results, with total revenue...
Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294), a pioneer in cardiorenal metabolic syndrome treatment in China,...
Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
Sanofi (NASDAQ: SNY) announced a leadership transition, with Paul Hudson stepping down as Chief Executive Officer...
Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application...
Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an...
Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer
Innovent Biologics, Inc. (HKG: 1801) announced first patient dosing in the pivotal Phase 3 HeriCare-Breast01 study...
Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) has entered a landmark licensing agreement with Madrigal...
Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
Novartis AG (NYSE: NVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope...
Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership between its PPD clinical research business...
MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
Merck & Co. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has...
Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a...
Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced first patient dosing in a Phase Ib/II clinical study...
Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy
Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) has submitted its IPO prospectus to the Hong Kong Stock...
PANACRO Pharma Files Hong Kong IPO to Expand Digital Clinical Research Platform
PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd., a China-based clinical contract research organization (CRO), has submitted...
Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...
Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that trastuzumab rezetecan (SHR-A1811), its HER2-targeted antibody-drug...
Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) announced plans for a private placement of up to...
uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO
uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...